According to our recent payer coverage analysis for non-small cell lung cancer BRAF+ treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for non-small cell lung cancer BRAF+ treatments shows that under the pharmacy benefit, about 71% of the lives under commercial formularies are covered with utilization management restrictions.
Trends: Coverage is under the pharmacy benefit. Prior authorization is required for both Mekinist and Tafinlar to ensure appropriate use. Payer policies for lung cancer typically follow National Comprehensive Cancer Network (NCCN) guidelines.
by Matt Breese